+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Recent advances in capsule-based dry powder inhaler technology



Recent advances in capsule-based dry powder inhaler technology



Multidisciplinary Respiratory Medicine 12: 11



Pulmonary drug delivery is currently the focus of accelerated research and development because of the potential to produce maximum therapeutic benefit to patients by directly targeting drug to the site of pathology in the lungs. Among the available delivery options, the dry powder inhaler (DPI) is the preferred device for the treatment of an increasingly diverse range of diseases. However, because drug delivery from a DPI involves a complex interaction between the device and the patient, the engineering development of this medical technology is proving to be a great challenge. Development of DPI systems that target the delivery of fine drug particles to the deeper airways in the lungs using a combination of improved drug formulations and enhanced delivery device technologies means that each of these factors contributes to overall performance of the aerosol system. There are a large range of devices that are currently available, or under development, for clinical use, however no individual device shows superior clinical efficacy. A major concern that is very relevant in day-to-day clinical practice is the inter- and intra-patient variability of the drug dosage delivered to the deep lungs from the inhalation devices, where the extent of variability depends on the drug formulation, the device design, and the patient's inhalation profile. This variability may result in under-dosing of drug to the patient and potential loss of pharmacological efficacy. This article reviews recent advances in capsule-based DPI technology and the introduction of the 'disposable' DPI device.

(PDF emailed within 0-6 h: $19.90)

Accession: 060174986

Download citation: RISBibTeXText

PMID: 28536654

DOI: 10.1186/s40248-017-0092-5


Related references

Pharmacokinetics of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler. Pulmonary Pharmacology and Therapeutics 29(1): 66-73, 2016

Comparison of the Pharmacokinetics of Salmeterol and Fluticasone Propionate 50/100 µg Delivered in Combination as a Dry Powder Via a Capsule-Based Inhaler and a Multi-Dose Inhaler. Clinical Drug Investigation 35(5): 319-326, 2016

Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients. Journal of Aerosol Medicine and Pulmonary Drug Delivery 27(4): 279-289, 2015

Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler in patients with asthma. Pulmonary Pharmacology and Therapeutics 41: 19-24, 2016

Use of a cognitive ergonomics approach to compare usability of a multidose dry powder inhaler and a capsule dry powder inhaler: an open-label, randomized, controlled study. Clinical Therapeutics 26(11): 1791-1799, 2005

Ease-of-use preference for the ELLIPTA® dry powder inhaler over a commonly used single-dose capsule dry powder inhaler by inhalation device-naïve Japanese volunteers aged 40 years or older. International Journal of Chronic Obstructive Pulmonary Disease 9: 1365-1375, 2015

Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler versus a multi-dose inhaler in patients with chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics 43: 12-19, 2017

Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Current Medical Research and Opinion 26(11): 2527-2533, 2011

Development of a high efficiency dry powder inhaler: effects of capsule chamber design and inhaler surface modifications. Pharmaceutical Research 31(2): 360-372, 2014

Pharmacokinetics of fluticasone propionate multidose, inhalation-driven, novel, dry powder inhaler versus a prevailing dry powder inhaler and a metered-dose inhaler. Allergy and Asthma Proceedings 36(5): 365-371, 2016

Multivariate Analysis of Effects of Asthmatic Patient Respiratory Profiles on the In Vitro Performance of a Reservoir Multidose and a Capsule-Based Dry Powder Inhaler. Pharmaceutical Research 33(3): 701-715, 2016

Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler. International Journal of Pharmaceutics 310(1-2): 81-89, 2006

Use of inspiratory profiles from patients with chronic obstructive pulmonary disease (COPD) to investigate drug delivery uniformity and aerodynamic dose emission of indacaterol from a capsule based dry powder inhaler. European Journal of Pharmaceutical Sciences 2019, 2019

Capsule opening arrangement for use in a powder inhaler. Official Gazette of the United States Patent & Trademark Office Patents 1263(5), Oct 29, 2002

Pharmacokinetics of Salbutamol Delivered from the Unit Dose Dry Powder Inhaler: Comparison with the Metered Dose Inhaler and Diskus Dry Powder Inhaler. Journal of Aerosol Medicine and Pulmonary Drug Delivery 30(3): 164-172, 2017